Nurix Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nurix Therapeutics, Inc. (Nasdaq: NRIX) on June 1, 2021, reporting events that occurred on May 28, 2021. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Director Resignation: Leon Chen, Ph.D., resigned as a Class II director and member of the Nominating and Corporate Governance Committee, effective immediately. The resignation is not due to any disagreement with the Company.
- Director Appointment: Clay B. Siegall, Ph.D., was appointed as a Class II director, effective immediately. He will serve on the Compensation Committee and the Development Advisory Committee. His term expires at the 2022 annual meeting of stockholders.
Compensation and Equity Grants
Dr. Siegall's compensation includes:
- Cash Retainers: Pro rata portions of the $35,000 annual director retainer, $5,000 Compensation Committee retainer, and $5,000 Development Advisory Committee retainer for the remainder of the fiscal year ending November 30, 2021.
- Initial Equity Award: A stock option to purchase 35,000 shares of common stock at the closing sale price on May 28, 2021. This award vests monthly over three years, subject to continued service.
- Annual Equity Award: Future annual awards consisting of options to purchase 17,500 shares, vesting on the earlier of the next annual meeting or one year from the grant date.
- Acceleration: Both the Initial and Annual Awards accelerate in full upon the consummation of a Corporate Transaction.
Risks and Contingencies
The filing states there are no family relationships between Dr. Siegall and other directors or officers, and no undisclosed material interests in transactions. The Company has entered into a standard indemnification agreement with Dr. Siegall.
Investor Verification Checklist
- Verify the impact of the board composition change on the Company's strategic direction.
- Review the press release (Exhibit 99.1) for additional context on the resignation and appointment.
- Confirm the vesting schedule and exercise price of the 35,000 share option granted to Dr. Siegall.
- Check subsequent filings for any changes to the Compensation Committee or Development Advisory Committee composition.